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Abstract
Background: Measuring quality of life (QOL) is an important means of assessing the impact of headache. The currently
used QOL questionnaires are usually geared toward migraine and focus on a limited number of factors, thus they are not
necessarily informative in other headache types. We report the psychometric properties of a new questionnaire, the
Comprehensive Headache-related Quality of life Questionnaire (CHQQ) that may be more sensitive to the burden of
headache.
Patients and methods: A total of 202 patients suffering from migraine (n¼ 168) or tension-type headache (TTH) (n¼ 34)
completed the CHQQ and SF-36, a generic QOL questionnaire. We assessed the reliability and validity of the CHQQ
and its physical, mental and social dimensions.
Results: The questionnaire was easy to administer. Reliability was excellent with Cronbach’s alpha being 0.913 for the
whole instrument (0.814–0.832 for its dimensions). The dimensions and total score showed significant correlations with
the patients’ headache characteristics (criterion validity), and were also significantly correlated with the SF-36 domains
(convergent validity). The total score and dimensions were significantly (p< 0.005) lower in the migraine group than in
the TTH group (discriminative validity).
Conclusion: In this study the new headache-specific QOL instrument showed adequate psychometric properties.
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Introduction
Primary headaches constitute a public health problem,
aﬀecting 46% of the adult population globally, causing
a signiﬁcant amount of disability (1) and poor health-
related quality of life (QOL) (2). Health-related QOL
reﬂects the patient’s perspective of the way medical
conditions and their treatment inﬂuence their position
in life. Measuring QOL can give a unique insight into
the patient’s condition as the doctor’s evaluation of
the eﬀect of illness can be markedly diﬀerent from the
patient’s perspective (3). Along with other patient-
reported outcomes that measure disability, illness intru-
siveness or other consequences of health problems,
measuring QOL has become an important means of
assessing the burden of disease and the eﬃcacy of thera-
peutic interventions (4).
QOL is measured by generic or disease-speciﬁc
questionnaires. Generic ones include questions that
represent those aspects of health that are important for
the majority of people. Thus, these instruments allow
broad comparisons of distinct conditions, can measure
the eﬀect of various healthcare interventions and
therefore can be useful, among others, in analysing
cost-eﬃciency or planning resource allocation in
health economics studies. Generic instruments may,
however, be unresponsive to changes in speciﬁc condi-
tions (5). There are numerous generic QOL instruments
in use, the most widely used being the Short Form
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Health Survey (SF-36) (6). Disease-speciﬁc QOL instru-
ments focus on problems associated with single disease
states, allow comparisons of illnesses which share the
leading symptoms, and can be helpful in selecting the
most appropriate therapy for the patient and monitor-
ing its eﬃciency. Moreover, they may better reﬂect the
particular impact of a selected condition.
QOL instruments study more domains of QOL. A
domain refers to a speciﬁc area of behaviour or experi-
ence, such as work performance, social functioning,
sleep, leisure activities, etc. The domains usually cover
the three main dimensions of health-related QOL: phys-
ical, mental and social (5), which have their roots in the
World Health Organization’s deﬁnition of health (7).
Since the 1990s several headache-speciﬁc QOL instru-
ments have been developed. These include the MSQ2.1
(Migraine-speciﬁc Quality of Life Questionnaire) (8), the
MSQOL (Migraine-Speciﬁc Quality of Life measure)
(9), the 24-hour MQoLQ (24-hour Migraine Quality of
Life Questionnaire) (10), and the French QVM (Qualite´
de Vie et Migraine) (11). In 2003 the 6-item Headache
Impact Test (HIT-6) was introduced. HIT-6 is an instru-
ment designed to measure headache impact, a concept
that is strongly related to QOL (12). We brieﬂy review
these instruments here.
The MSQ2.1 is the current 14-item version of the
former 16-item Migraine Speciﬁc Questionnaire. It
measures three dimensions of headache impact: role-
restrictive, role-preventive and emotional function.
MSQ2.1 was found to be a reliable and valid means of
assessing QOL in migraine and has been formally vali-
dated for patients undergoing prophylactic migraine
treatment (13). It has also been used in cluster headache
(14). Recently, MSQ2.1 was validated for clinical use in
episodic and chronic migraine (15) and was found to
demonstrate signiﬁcant diﬀerences between these, with
chronic migraine suﬀerers having lower values in all
dimensions.
The MSQOL is a 25-item instrument that was found
to be a valid and reliable measure for cross-sectional
comparisons that encompass a migraine patient’s sub-
jective well-being (9). Further testing of the instrument
revealed three dimensions (avoidance, relationships and
feelings) and provided evidence for the calculation of a
total score (16). Interestingly, another group described
a diﬀerent structure of the MSQOL with four dimen-
sions (physical, psychical, social and life rhythms) in a
study of patients with migraine or tension-type head-
ache (TTH) (17) The MSQOL has been successfully
used as an outcome measure in prophylactic drug
trials for migraine (18).
The MQoLQ was developed to measure the acute
changes in QOL in migraineurs during a migraine
attack. The questionnaire has 15 items grouped in ﬁve
domains: work functioning, social functioning, energy,
feelings/concerns, and migraine symptoms. In the
validation study the domains showed good internal
consistency and construct and discriminant validity,
and responsiveness to acute migraine attacks. It
detected signiﬁcant changes of QOL during the acute
migraine attack. Moderate to strong negative correl-
ations were found between QOL and headache severity,
limitations of activity, number of migraine symptoms,
and headache duration (10). The MQoLQ was vali-
dated and primarily used among migraineurs, but also
as an endpoint in drug trials (19), and it was found to
be useful in the long-term follow-up of chronic head-
ache patients (20).
QVM is a French migraine-speciﬁc QOL instrument,
with four domains: psychological, somatic, social reper-
cussion and disturbance generated by the treatment.
In the validation study, the reliability assessed by
test–retest reproducibility was good (r 0.70–0.80).
In a later study on a nationwide sample, frequency,
severity and treatment resistance of headaches, as well
as headache-related disability, were signiﬁcantly corre-
lated with QVM’s total score and subscales; correlation
coeﬃcients were not reported (21). QVM was used in
many French studies, including acute drug trials in
migraine (22) and also in patients with chronic daily
headache (21) and TTH (23).
The HIT-6 covers six content categories represented
in widely used surveys of headache impact, including
social and role functioning, vitality, cognitive function-
ing and psychological distress. It was developed using
an existing item pool of 54 items and from 35 items
suggested by clinicians, using advanced methods of
item response theory. In a large study, HIT-6 was
found to be eﬃcient, reliable and valid for the screening
and monitoring of patients with headache (12).
Subsequently, it has been extensively used in clinical
practice, and applied in studies measuring headache
impact and also in drug trials in migraineurs. The
HIT-6 has been validated in episodic and chronic
migraine using ID-migraine and a headache diary for
diagnostic purposes (24). It has also been used in
chronic daily headache (25) and TTH (26).
Owing to the availability of these instruments, there
is a signiﬁcant amount of scientiﬁc evidence about the
negative eﬀect of episodic and chronic migraine, cluster
headache (2,14,27), TTH (28) and chronic daily head-
ache (29) on generic and headache-speciﬁc QOL. The
eﬀects of acute (19,22) and prophylactic (13,18,30)
migraine treatment on QOL have also been docu-
mented. There are, however, some observations that
raise the possibility that currently available instruments
do not fully capture patients’ perceptions. Despite the
obvious diﬀerences in the clinical picture and the
patients’ complaints, there were only a few diﬀerences
between the generic QOL proﬁles of migraine, cluster
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headache and TTH (31). The SF-36 proﬁles of migraine
and cluster headache were also very similar, and in the
same study, MSQ2.1 did not show any diﬀerence
between the QOL proﬁles of cluster headache patients
and migraineurs (14). Moreover, a clinically eﬀective
therapy is not necessarily reﬂected by an improvement
of the QOL scores of migraineurs (32). Patients may
also feel that the instruments do not capture some
important areas of their QOL, as was the case of our
patients (suﬀering from cluster headache or migraine)
during the above-mentioned trial (14).
Besides these observations there is a methodological
caveat when using headache-speciﬁc QOL instruments:
all the above-described instruments were developed to
assess the QOL in migraine. Based on PubMed and
Scopus searches, only MSQ2.1 and HIT-6 have been
psychometrically validated for chronic migraine, and
none have been validated in other headache types.
Taken together, these limitations suggest that an
instrument probing several important facets of life
and validated in diﬀerent headache types may provide
patients and healthcare providers with more precise
information about QOL in headache. In order to test
this hypothesis, we have decided to develop a com-
prehensive headache-speciﬁc questionnaire, assessing
several aspects of QOL. A preliminary study in
migraineurs found that the psychometric properties of
this questionnaire were adequate for further testing
(33). Three dimensions (physical, mental and social)
were constructed based on item content. Exploratory
factor analysis with varimax rotation found that a
single factor accounted for 47% of the total variance,
while a second factor was responsible for 3.7%, and
further factors accounted for even smaller amounts of
variance: this was interpreted as the basis of calculating
a total score (34).
Objective
The aim of the present study was to assess the psycho-
metric properties of the headache-speciﬁc questionnaire
on a large group of headache patients suﬀering from
migraine and TTH. The main hypotheses were the
following:
1. The questionnaire’s internal consistency will be ade-
quate (Cronbach’s alpha >0.7) in the total sample
and both headache types.
2. The individual’s QOL, as indicated by the items,
domains and total score, will be negatively
correlated with clinical characteristics of their
headache.
3. The new questionnaire’s items, domains and total
score will be positively correlated with the relevant
domains and total score of the SF-36 measure.
4. Patients with TTH will have a better QOL (higher
scores on the instrument) than patients suﬀering
from migraine.
Patients and methods
Patients
Consecutive outpatients visiting the headache centre of
the Department of Neurology, Semmelweis University,
in 2008–2010, who fulﬁlled the International Headache
Society (IHS) criteria (35) for migraine with and
without aura (episodic type; ICHD-II codes 1.1 and
1.2) or TTH (either episodic or chronic; ICHD-II
codes 2.1–2.3) took part in the study. We excluded
patients suﬀering from the rare adult migraine subtypes
(hemiplegic migraine, basilar-type migraine, retinal
migraine and complications of migraine (ICHD-II
codes 1.2.4–1.2.6, 1.3–1.5). According to the IHS
criteria, patients meeting one of the sets of criteria for
probable TTH (2.4) may also meet the criteria for one
of the subforms of probable migraine (1.6), therefore
we also excluded patients with the diagnosis of prob-
able migraine and probable TTH in order to minimize
the chance of misdiagnosing the patients. Patients
whose analgesic consumption reached the criteria of
analgesic abuse (36) were also excluded, as were
patients who also had concomitant chronic pain syn-
dromes, untreated hypertension, and untreated or
severe kidney or liver disease. Other concomitant
treated disorders were not excluding criteria, but their
possible eﬀect on QOL was not taken into account in
the statistical analysis. All patients had headache as the
main complaint at the time of the study.
Methods
Development of the new questionnaire. The development of
the questionnaire consisted of three major steps: rele-
vant item identiﬁcation, formation and psychometric
testing of a draft version, and the development of the
ﬁnal version. First one of the authors (CE) conducted
open interviews with 25 persons suﬀering from the most
important primary headache types (10 migraine (M), 10
TTH and 5 cluster headache (CH) patients). The ques-
tions for these interviews were based on the experience
of ﬁve clinicians and literature reviews of QOL in head-
aches and other pain conditions. A question was con-
sidered a potential item if at least two clinicians and
two patients from each diagnostic group felt the
respective issue was important. Twelve of the 37
original questions were found redundant or insigniﬁ-
cant and therefore removed, resulting in a 25-item
draft version.
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In a second step, 11 migraineurs from a larger group
studied for the eﬀect of migraine (37) were asked to
complete the draft version and were then interviewed
about it. These interviews were used to determine
whether each individual understood the items, felt
them meaningful and whether they felt the answer cate-
gories were suﬃcient. Minor changes of content and
format were applied accordingly.
Third, the 25-item questionnaire was tested in a
group of 117 migraineurs (33) and quality criteria for
item selection (9) applied. There was no ceiling eﬀect in
the sample. One item asking about the inﬂuence of
headache on parental responsibilities (‘How much do
your headaches interfere with your role as a parent?’)
had by far the biggest proportion of missing answers
(31% of the sample; mostly patients with grown-up
children or no children) and therefore was not included
in the ﬁnal version. An item about prophylactic medi-
cation use (‘How often have you used prophylactic
treatment for your headaches?’) had a very low
(0.214) item-total correlation: analysis of the clinical
data revealed that beside those who regularly took a
prophylactic medicine, a signiﬁcant part of the study
population considered the early administration of
acute medications as ‘prophylactic’ treatment. This
item was also problematic because taking a migraine
prophylactic is the joint decision of the patient and
the physician and therefore it is less likely to reﬂect
the patient’s QOL. Therefore this item was also omitted
from the ﬁnal version of the questionnaire. The reliabil-
ity and validity assessments conﬁrmed that the resulting
23-item questionnaire was adequate for further testing.
Description of the instruments used in the study. The 23-item
QOL questionnaire, hereafter referred to as the
Comprehensive Headache-related QOL Questionnaire
(CHQQ), examines the impact of headache on QOL
in detail. The questions cover the 2 weeks before the
data recording. All questions have ﬁve possible answers
(5-point Likert scale), ranging from the absolute
absence of restriction to maximal restriction. After
scoring, the values are transformed to a 0–100 point
scale, the absence of restriction being equal to 100
points and the full restriction to 0 points (6). Total
score and the three dimensions (physical, mental and
social) are calculated; they are the mean values of the
relevant transformed item scores (the item scores are
not weighted).
Generic QOL was measured with the validated
Hungarian version of the SF-36 questionnaire (38).
The SF-36 is one of the most frequently used generic
QOL instruments. It examines eight QOL domains:
four domains represent physical (physical functioning,
role-physical, bodily pain, general health) and four
mental health concepts (vitality, social functioning,
role-emotional, mental health) (6). Widely accepted as
it is, the SF-36 is far from examining all notable aspects
of QOL. Among other aspects, the SF-36 does not col-
lect data about sleep and its quality, cognitive features,
leisure activities, sexual life, self-conﬁdence, worries,
and the quality of interpersonal communication.
Data recording. The patients all completed the validated
Hungarian version of the SF-36 and the CHQQ in the
Headache Unit, after their outpatient visit; the ques-
tionnaires were administered by the headache specialist
seeing outpatients on the given day. The questionnaires
were ﬁlled in on the spot and given back to the staﬀ.
Missing data were not complemented. The patient’s
headache characteristics and other clinical data were
recorded during their clinical interview. Headache
severity was assessed by the patient (visual analogue
scale (VAS); 0–100mm) and also by the specialist
during the clinical interview (IHS rating scale, 0¼ pain
free, 1¼mild, 2¼moderate, 3¼ severe). Headache
diagnoses were made by the same headache specialists
during the outpatient visit, using the IHS criteria.
Depression was not formally tested during the visit.
As this was a validation study, the data were not used
in the evaluation of the patient’s functional status, dis-
ease severity or therapeutic needs.
Statistical methods. The validation of a questionnaire
requires testing its reliability and validity. Reliability
is the degree to which a test consistently measures
what it aims to measure. The methods of assessing
reliability include the test–retest method, the use of
two alternative questionnaires (the equivalence of
which requires prior statistical evaluation) or measur-
ing the internal consistency of the instrument by
calculating the split-half reliability, or Cronbach’s
alpha. To assess the reliability of our questionnaire,
we calculated the Cronbach’s alpha for the whole
instrument and its dimensions.
Validity refers to the degree to which an instrument
can accurately assess the speciﬁc concept that the
research is attempting to measure (5). We used several
methods to assess the validity of the instrument. First
we examined the correlation of the patient’s headache
characteristics with the questionnaire’s items, dimen-
sions and total score (criterion validity). We then exam-
ined the correlation of the individual items, the three
dimensions and the total score with the domains of the
SF-36 measure, a means of assessing convergent valid-
ity. In these analyses the degree of correlation was mea-
sured by calculating Spearman’s rank correlation
coeﬃcient. We also assessed discriminative (known
groups) validity, by comparing the results of the instru-
ment in the two diagnostic groups, M and TTH, using
Mann–Whitney tests.
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In the preliminary validation study items were
grouped in the three classical dimensions of QOL
instruments (physical, mental and social) according to
their content. In order to assess the structure of the
instrument we performed an analysis of item-dimension
correlations using Spearman’s rank correlation
coeﬃcients.
Statistics were calculated using Statistica 8.0 soft-
ware. The level of signiﬁcance was set to p< 0.05.
The study was approved by the Regional and
Institutional Committee of Science and Research
Ethics of Semmelweis University.
Results
Observations about completing the questionnaire
The questionnaires were administered to a total of 217
patients. On average, it took less than 20 minutes to
complete both of the questionnaires. Filling in the ques-
tionnaire did not present any diﬃculty, as reported by
the patients. The majority of the patients answered all
questions. Of CHQQ’s 23 questions, 13 had no missing
answers. Fifteen participants did not answer the ques-
tion about the inﬂuence of their headaches on their sex
life. For the remaining nine questions, the rate of miss-
ing answers was very low (1 to 3 per question). All
questions were completely answered by 202 patients
(93% of the 217 patients). As Statistica excludes sub-
jects with missing data from reliability and validity ana-
lyses, these were calculated taking the 202 patients into
account.
Patient characteristics
Among the 202 patients we studied 169 were
females and 33 were male. The mean age was 35.1
years, (SD 11.53; range 18–68). All patients were
Caucasian. One hundred and forty-one patients were
in paid employment (70%), 20 were students (10%),
10 were on maternity leave (5%), 9 were retired
(4.5%) and 3 unemployed (1.5%); 19 preferred not to
answer the question about employment status.
One hundred and sixty-eight patients (83.2%) were
migraineurs and 34 patients (16.8%) had TTH (11 epi-
sodic and 23 chronic). Patients with chronic TTH had a
signiﬁcantly higher attack frequency (mean 33.5, SD
13.5 vs. mean 6.5, SD 4.0, p< 0.001) and more head-
ache days (mean 27.7, SD 5.07 vs. mean 7.61, SD 4.33,
p< 0.001) but smaller minimum (mean 1.97, SD 1.56
vs. mean 4.91, SD 6.19 hours, p¼ 0.027) and maximum
(mean 9.4, SD 6.67 vs. mean 33.71, SD 24.0 hours,
p< 0.001) lengths of treated attack than patients with
episodic TTH. Other headache characteristics were not
signiﬁcantly diﬀerent in the chronic and episodic TTH
groups. The male:female ratio was non-signiﬁcantly
higher in the chronic group (10 males and 13 females
vs. 2 males and 9 females, p¼ 0.252, Fisher’s exact test).
Fifty-three patients (26.2%) also had a history of
depression. Of these, 42 were migraineurs and 11
TTH patients (4 episodic and 7 chronic). Depression
occurred in 25% of the migraine group and 32% of
the TTH group (p¼ 0.396, Fisher’s exact test). Data
about the patient group are presented in Table 1.
Reliability
The questionnaire demonstrated excellent reliability,
with Cronbach’s alpha being 0.913 for the whole
sample, 0.892 in the subgroup of migraineurs and
0.928 in the subgroup of TTH patients. The physical,
mental and social dimensions also showed good reli-
ability in the whole population and also in the diagnos-
tic subgroups (Table 2).
Table 1. Patient characteristics.
Variable All M TTH p (M vs. TTH)
Age (years) 35.1 11.5 34.77 10.8 36.20 14.5 0.899
Disease duration (years) 12.23 10.4 13.31 10.1 6.80 10.4 <0.001
Minimum length of treated attack (hours) 10.8 12.9 11.51 13.5 7.48 9.6 0.004
Maximum length of treated attack (hours) 41.15 31.7 45.72 32.6 19.91 14.2 <0.001
Mean attack length (hours) 24.8 20.9 27.61 21.5 11.00 9.5 <0.001
Headache severity (IHS rating scale) 2.32 0.6 2.45 0.5 1.68 0.5 <0.001
Headache severity (VAS) 67.52 21.1 72.13 18.0 46.94 20.9 <0.001
Attack frequency last month 7.49 10.8 4.10 3.6 24.13 17.4 <0.001
Number of days with headache last month 8.59 8.2 6.14 4.6 20.54 11.3 <0.001
Data are presented as mean SD. All: all patients; M: migraine group; TTH: tension-type headache group; IHS: International Headache Society; VAS:
visual analogue scale.
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Validity
Criterion validity. In the whole sample, headache severity
was negatively correlated with almost all items (22
items correlated signiﬁcantly with the VAS and 21
with the IHS headache severity scale). Mean attack
length and attack frequency showed signiﬁcant negative
correlations with 19 and 13 items, respectively. Age and
length of disease were the clinical variables that showed
signiﬁcant correlations with the smallest amount of
items (Table 3). The results were similar in the sub-
group of migraineurs. In the TTH subgroup, headache
severity (measured in both ways) and age were nega-
tively correlated with six items each. Other clinical data
showed signiﬁcant correlations with a smaller number
of items.
In the whole sample, the physical dimension of the
instrument was signiﬁcantly correlated with all clinical
characteristics. The mental dimension was signiﬁcantly
correlated with six of the nine clinical characteristics
(the exceptions being attack frequency, headache days
per month and maximum length of attacks). The social
dimension was correlated with eight of the nine clinical
characteristics; age did not show a signiﬁcant correl-
ation with this dimension.
In the migraine subgroup most correlations were
also signiﬁcant. Neither dimension was correlated
with the number of headache days per month, the men-
tal dimension was not correlated with attack frequency
and the maximum length of attacks, and the social
dimension was not correlated with age. In the TTH
group the questionnaire’s physical and social dimen-
sions were negatively correlated with headache severity,
whereas the mental dimension showed no signiﬁcant
correlation with the clinical characteristics.
In the whole sample the total score of the instrument
correlated signiﬁcantly with seven of the nine headache
characteristics; there was no signiﬁcant correlation with
age and the number of headache days per month. In the
subgroup of migraineurs the total score also showed
signiﬁcant correlations with most (7/9) clinical data,
the exceptions being attack frequency and days with
headache in the last month. There were no signiﬁcant
correlations between the clinical data and the total
score in the subgroup of patients with TTH.
Convergent validity. In the whole group, and also in the
diagnostic subgroups (migraine and TTH), the majority
of items relevant to physical functioning showed signiﬁ-
cant correlations with the physical domains of SF-36,
especially with the bodily pain and role-physical
domains. The mental and social items of the instrument
correlated with the four mental health domains of
S0F-36, particularly with social functioning and
mental health. The questions asking about general
health perceptions and irritability correlated signiﬁ-
cantly with all eight domains of the SF-36, and six
more items showed signiﬁcant correlations with seven
SF-36 domains (Table 4).
The physical dimension of the new instrument
showed signiﬁcant correlations with all ‘physical’
domains of the SF-36 in the total sample and also in
the M and TTH groups, except for the correlation with
SF-36’s bodily pain domain in the TTH group. The
mental dimension had signiﬁcant correlations with all
SF-36 domains, with the exception of the correlation
with the role-emotional domain in TTH patients.
The social dimension had signiﬁcant correlations
with the majority of SF-36 domains, except for the
role-emotional SF-36 domain, which was signiﬁcantly
correlated with it only in the TTH group, and the
physical functioning SF-36 domain, which was not sig-
niﬁcantly correlated with the social dimension in TTH
suﬀerers.
The total score of the instrument correlated signiﬁ-
cantly with all SF-36 domains in the whole sample and
in the migraine group; the total scores in the TTH
group did not correlate with the social functioning
domain of SF-36, but showed signiﬁcant correlations
with all other SF-36 domains.
Discriminative validity. When comparing the results of the
two diagnostic groups (M and TTH), we found that
patients suﬀering from TTH had higher scores (better
QOL) at each item. The diﬀerence was signiﬁcant for 16
of the 23 items (8/8 items of the physical dimension, 4/5
items of the social dimension and 3/10 items of mental
dimension) (Table 5). The diﬀerences between M and
TTH on CHQQ’s three dimensions and total score were
also highly signiﬁcant (p< 0.004); again, TTH suﬀerers
had higher scores (better QOL).
Within the TTH group, there was no signiﬁcant dif-
ference in the CHQQ scores (items, dimensions and
total score) of episodic and chronic patients, apart
from work performance (p¼ 0.014) and physical
health (p¼ 0.016), which were more severely aﬀected
in chronic TTH.
Table 2. The reliability of the questionnaire and its main
dimensions: Cronbach’s alpha values.
Migraine
group
TTH
group
Whole
sample
Whole questionnaire 0.892 0.928 0.913
Physical dimension 0.819 0.807 0.832
Mental dimension 0.801 0.874 0.814
Social dimension 0.814 0.846 0.829
TTH: tension-type headache.
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Dimension structure of the questionnaire
In order to examine whether the individual items were
mathematically related to the hypothesized dimensions
of the instrument, we performed an analysis of item–
dimension correlations on the sample. Spearman’s rank
order correlations were signiﬁcant for all items and all
dimensions. With the exception of the Energy item
(which showed the highest correlation with the
Physical dimension), all the items showed the highest
correlation with their intended dimensions (these data
are not shown in the tables).
Observations of the SF-36 measure
In order to compare the performance of the new ques-
tionnaire and the SF-36, we calculated the correlations
between the SF-36 domains and the clinical character-
istics. In general, signiﬁcant correlations were rare and
of low to moderate strength. In the whole sample
attack frequency was negatively correlated with role-
physical, vitality, role-emotional and mental health
domains, and headache severity was negatively corre-
lated with the role-physical and bodily pain domains.
In the migraine group attack frequency was not cor-
related with any SF-36 domain, and headache severity
was negatively correlated with the role-physical and
bodily pain domains. In the TTH group attack
frequency was negatively correlated with the role-
physical and bodily pain domains, and headache
severity with the bodily pain domain (these data are
not shown in the tables).
We also assessed the discriminative validity of the
SF-36 measure in the two groups. Patients suﬀering
from TTH had signiﬁcantly higher scores (reﬂecting
better QOL) in two of the eight dimensions (role-
physical and bodily pain), whereas migraineurs had
numerically higher scores in six domains, the diﬀerence
being signiﬁcant only in two, vitality and mental health
(Table 6).
Discussion
We evaluated the psychometric properties of the
Comprehensive Headache-related QOL Questionnaire
(CHQQ), a new headache-speciﬁc QOL instrument in
patients suﬀering from migraine or TTH headache.
The questionnaire was easy to administer. The internal
consistency of the questionnaire was excellent in the
whole sample and also in the diagnostic subgroups.
Tests of criterion and convergent validity were also
adequate. The questionnaire was able to detect signiﬁ-
cant diﬀerences between the impact of migraine and
TTH. The dimension structure of the instrument was
conﬁrmed. Thus, CHQQ seems to be a reliable andT
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valid means of measuring the impact of headache on
the individual’s QOL.
The study population consisted of patients with epi-
sodic migraine and TTH. Patients with episodic and
chronic TTH had very similar clinical characteristics
(apart from attack frequency and number of days with
headache) and similar QOL proﬁles (no signiﬁcant dif-
ferences were found in 21/23 items, 3/3 dimensions and
the total score), and therefore were treated as a single
group. The reason for this similarity may be the fact that
patients were recruited at a tertiary centre and patients
with infrequent TTH or those whose headache did not
cause a certain amount of impairment were not referred
to this centre for evaluation.
The study population may have been larger if
patients with probable migraine and probable TTH
Table 4. Convergent validity: The correlation of the questionnaire’s individual items, dimensions and total score with the SF-36
instrument. Marked correlations (bold and italic) are statistically significant (p< 0.05). For the sake of brevity only the whole group’s
results are presented about the correlation of the individual items and SF-36 domains.
PF RP BP GH VT SF RE MH
Work performance All 0.085 0.371 0.601 0.117 0.005 0.239 0.000 0.032
Household chores All 0.086 0.305 0.455 0.090 0.012 0.186 0.019 0.024
Social life All 0.026 0.320 0.439 0.020 0.005 0.195 0.037 0.016
Leisure activities All 0.074 0.297 0.394 0.061 0.016 0.147 0.005 0.014
Vacations/awaydays All 0.183 0.392 0.431 0.138 0.028 0.221 0.069 0.048
Physical health All 0.204 0.416 0.495 0.101 0.065 0.221 0.030 0.007
Appearance All 0.023 0.292 0.406 0.036 0.053 0.264 0.063 0.030
Intrafamiliar relations All 0.150 0.337 0.384 0.188 0.206 0.345 0.097 0.201
Sex life All 0.108 0.328 0.367 0.046 0.021 0.160 0.048 0.006
Sleep All 0.262 0.231 0.345 0.135 0.163 0.223 0.129 0.152
Energy All 0.134 0.222 0.306 0.109 0.104 0.116 0.125 0.131
Mood All 0.116 0.080 0.222 0.105 0.171 0.130 0.069 0.246
Memory All 0.277 0.045 0.155 0.267 0.254 0.289 0.251 0.298
Concentration All 0.289 0.128 0.171 0.300 0.187 0.310 0.254 0.238
Thinking All 0.095 0.213 0.299 0.192 0.219 0.332 0.149 0.288
General health perceptions All 0.279 0.358 0.262 0.400 0.214 0.268 0.254 0.256
Irritability All 0.170 0.209 0.283 0.183 0.230 0.344 0.205 0.246
Frustration All 0.128 0.128 0.205 0.223 0.220 0.301 0.202 0.308
Abortive medication use All 0.153 0.168 0.233 0.036 0.026 0.235 0.038 0.008
Financial situation All 0.185 0.203 0.289 0.034 0.026 0.197 0.007 0.010
Embarrassment due to headaches All 0.073 0.254 0.141 0.074 0.023 0.127 0.136 0.067
Worries about headaches All 0.148 0.181 0.326 0.221 0.102 0.299 0.129 0.197
Life enjoyment All 0.212 0.195 0.195 0.334 0.354 0.336 0.109 0.350
Physical score All 0.252 0.419 0.503 0.186 0.117 0.318 0.109 0.142
M 0.270 0.343 0.487 0.204 0.142 0.346 0.131 0.185
T 0.428 0.454 0.338 0.437 0.460 0.245 0.374 0.440
Mental score All 0.263 0.318 0.384 0.378 0.254 0.436 0.256 0.351
M 0.252 0.249 0.335 0.378 0.267 0.411 0.254 0.373
T 0.492 0.593 0.545 0.676 0.567 0.536 0.378 0.589
Social score All 0.221 0.414 0.500 0.219 0.234 0.392 0.101 0.204
M 0.233 0.291 0.431 0.200 0.268 0.405 0.098 0.245
T 0.321 0.649 0.580 0.637 0.575 0.416 0.420 0.523
Total score All 0.270 0.413 0.525 0.291 0.203 0.443 0.188 0.264
M 0.274 0.338 0.478 0.295 0.235 0.429 0.179 0.304
T 0.498 0.645 0.553 0.778 0.591 0.458 0.486 0.512
All: all patients; M: migraine group; T: tension-type headache group.
SF-36 domains: PF, physical functioning; RP, role-physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role-emotional; MH,
mental health.
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had been included. We decided not to include these
patients to avoid diagnostic errors, as the IHS classiﬁ-
cation foresees a diagnostic overlap between these two
headache types. We also aimed to deﬁne clearly distin-
guishable diagnostic groups because we felt that the
assessment of discriminative validity could have been
compromised by including the respective ‘probable’
cases. On the other hand, as the present study con-
ﬁrmed the questionnaire’s ability to discriminate the
eﬀect of migraine and TTH, it would be interesting to
investigate whether there is any meaningful diﬀerence
between the QOL proﬁles of patients with ‘probable’
and ‘deﬁnitive’ migraine or other forms of headache.
The length and ease of use of a questionnaire are
important aspects of its usability (39) and questionnaire
length can have a threshold eﬀect on response rate (40).
In our study the questionnaire did not present any dif-
ﬁculty for the patients and 93% ﬁlled in all questions.
The question about the eﬀect of headache on sex life was
the most frequently unanswered one (7% of the
patients), much lower than the 17% missing answers
for a similar question in a French QOL study (21). The
other questions were answered by more than 98% of the
participants; equally high answer rates had been
observed in previous studies of QOL in headache
(9,21). The high response rate indicates that the length
of this questionnaire will probably not be a signiﬁcant
limiting aspect of its clinical use. While shorter QOL
instruments can clearly have an important role in every-
day practice (41), longer instruments such as the CHQQ
may present a more detailed QOL proﬁle, which could
be especially useful in the areas of clinical and pharma-
coeconomic research and/or healthcare planning.
In assessing the reliability of a questionnaire,
the repeated application of the same questionnaire
(test–retest analysis) is an alternative to measuring
Table 5. Discriminative validity: item, dimension and total scores (mean SD) of the migraine group versus the
tension-type headache group.
Mean SD (M) Mean SD (TTH) p level
Work performance 32.74 25.50 51.47 24.26 <0.001
Household chores 31.85 25.74 54.41 26.83 <0.001
Social life 29.17 27.40 52.21 30.5 <0.001
Leisure activities 27.98 25.00 53.68 27.24 <0.001
Vacations/awaydays 43.30 35.56 69.12 32.89 <0.001
Physical health 30.06 26.82 58.09 29.25 <0.001
Appearance 40.62 24.81 61.03 25.24 <0.001
Relationship with other family members 42.11 24.83 58.82 27.67 <0.001
Sexual life 35.57 33.20 61.03 32.61 <0.001
Sleep 38.80 29.23 50.74 29.16 0.030
Energy 31.99 19.3 42.65 20.11 0.002
Mood 28.57 19.86 36.03 22.41 0.080
Memory 65.48 30.39 73.53 25.68 0.177
Concentration 37.65 26.10 55.15 24.39 <0.001
Thinking 43.75 25.53 62.50 26.58 <0.001
General health perceptions 54.46 26.86 70.59 27.50 0.001
Irritability 44.20 32.19 52.21 35.59 0.252
Frustration 39.43 28.11 44.85 26.44 0.298
Abortive medication use 22.62 27.6 44.85 40.34 0.005
Financial situation 68.01 28.51 77.21 29.56 0.039
Embarrassment due to headaches 82.44 27.39 89.71 23.09 0.073
Worries about headaches 39.14 25.98 47.79 30.50 0.170
Life enjoyment 44.94 30.81 54.41 25.35 0.052
Physical dimension 35.84 19.29 56.53 18.76 <0.001
Mental dimension 45.77 17.75 55.88 17.39 0.004
Social dimension 42.11 22.01 62.21 21.27 <0.001
Total score 41.52 17.24 57.48 16.87 <0.001
Marked differences (bold and italic) are significant (p< 0.05, Mann–Whitney tests). Higher scores reflect a better QOL. M: migraine
group; TTH: tension-type headache group.
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internal consistency. Test–retest analysis usually
requires a 4-week period between the two test sessions
in order to avoid recall bias. During this period the
patient’s therapy should be unchanged. As the majority
of our patients clearly needed a change in their acute
medications (and a signiﬁcant portion also needed
prophylactic therapy), this method would have been
ethically incorrect and so was not applied in this
study. Internal consistency is generally considered ade-
quate if Cronbach’s alpha exceeds 0.7, and considered
excellent with values in excess of 0.9; if an instrument is
to be used in the clinical setting, rather than for the
comparison of groups only, an alpha exceeding 0.9 is
the minimum requirement (42). In this respect CHQQ
seems to be adequate for use as a follow-up tool in
individual patients, but we underline that formal clin-
ical testing should precede its use for this purpose. On
the other hand, CHQQ’s reliability is comparable to
that of MSQ2.1 and quite noticeably better than the
reliability of the MSQ, the dimensions of which had
internal consistency values between 0.70 and 0.85 (8).
A high-quality QOL instrument is required to dem-
onstrate content validity, criterion and construct validity
(43). Content validity expresses the degree to which the
underlying construct (QOL) is comprehensively sampled
by the instrument’s items (5). Unlike other forms of val-
idity, content validity cannot be formally tested, but is
assured by (and can be judged by) the methods followed
at the instrument’s development process. We followed
the recommendations outlined in (5) and (43) during the
development phase of CHQQ. Consequentially, the
items included in the ﬁnal version were the ones that
were meaningful both for the patients and the clinicians
involved. The small number of missing responses may
also reﬂect that the patients felt the questions covered
important aspects of their condition – another aspect of
content validity. It is therefore reasonable to suggest that
the instrument’s content validity is adequate.
The instrument’s validity was formally assessed by
measuring its criterion, convergent and discriminative
validity. Criterion validity is usually deﬁned as the
extent to which scores of an instrument are related to
a criterion measure, i.e. a measure of the target con-
struct that is widely accepted as a valid representative
of that construct (44). The criterion measure can be a
previously validated instrument measuring a similar
construct, or a clinical variable that is conceptually
related to the construct that the new instrument pur-
ports to measure. In headache research, the clinical
characteristics of the individual’s headaches are fre-
quently used as criterion measures. In line with the pre-
sent study, most QOL instruments had low to moderate
correlations with the clinical data. During the valid-
ation of the MSQ2.1 measure, self-reported frequency
and severity of headaches, duration of the attacks, and
the time since the last severe headache were used to test
for criterion validity (8). These showed signiﬁcant but
moderate correlations with the MSQ2.1 dimensions
and total score. The validation study of the MQoLQ-
24 (10), an instrument designed for assessing the acute
changes in QOL during a migraine attack, found that
most correlations between the instrument’s domains
and clinical data were moderate: the strongest correl-
ations were between the work domain of the instrument
and limitation of activity (r¼0.30 to 0.51); the
weakest correlations were seen with the concerns/feel-
ing domain, but even there, the strongest correlation
was with activity limitation (r¼0.19 to 0.41). In
the validation study of the French QVM instrument,
the frequency, severity, and treatment resistance of
headaches, as well as headache-related disability, were
signiﬁcantly correlated with QVM’s total score and
subscales; correlation coeﬃcients were not reported
(21). During the validation study of the MSQOL cor-
relations with clinical variables were not calculated;
instead, groups were created according to the severity
of clinical symptoms and ANOVAs of MSQOL scores
calculated: increased disease severity was associated
with worse QOL (9).
In the present study more severe external measures
of headache were related to a worse QOL. The strength
of the correlations we observed (weak to moderate) was
comparable to those found in the above-mentioned stu-
dies. The strength of correlations, and the fact that the
items, dimensions and total score of the instrument did
not correlate signiﬁcantly with all clinical data, are not
surprising: the symptoms of a disease do not invariably
correlate with QOL scores (45). This is partly explained
by the fact that the items in a QOL instrument can be
divided into two main types: causal indicators and
eﬀect indicators. Studies of the relationship between
symptoms and QOL indicate that while some symp-
toms, such as obstipation, vomiting or hemiparesis,
Table 6. Discriminative validity of the SF-36 questionnaire.
SF-36 scores of the migraine and TTH groups (mean SD)
SF-36 domain M TTH p value
PF 78.94 27.78 76.89 29.07 0.383
RP 32.12 45.43 61.49 43.54 <0.001
BP 29.83 20.24 40.95 20.51 0.002
GH 59.34 22.23 54.31 18.51 0.091
VT 54.97 20.93 47.16 20.09 0.030
SF 63.33 23.55 62.50 21.13 0.895
RE 65.19 46.28 50.40 44.14 0.052
MH 64.87 20.64 54.81 19.16 0.004
M: migraine group; TTH: tension-type headache group.
SF-36 domains: PF, physical functioning; RP, role-physical; BP, bodily pain;
GH, general health; VT, vitality; SF, social functioning; RE, role-emotional;
MH, mental health.
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are almost always evident before, and have a direct
inﬂuence on the deterioration of QOL (causal indica-
tors), other symptoms including pain, anxiety or
depression probably have a bidirectional relationship
with QOL (eﬀect indicators) (46). It is also important
to note that diﬀerent symptoms or aspects of their
conditions can have diﬀering importance for primary
headache patients. This is exempliﬁed by studies of the
determinants of patient satisfaction with migraine
treatment, with fast and complete headache relief
being described by most migraineurs as their main pref-
erence, and freedom from associated symptoms being
important for a smaller number of patients (47). The
diﬀerence in the frequency of accompanying symptoms
within the study populations (48) may also inﬂuence the
correlations between clinical data and QOL scores.
Finally, it must be borne in mind that, theoretically,
symptom scores and QOL instruments measure two
fundamentally diﬀerent constructs, and the correlations
we found support this notion.
While the CHQQ scores of migraineurs showed sig-
niﬁcant correlations with most clinical data, the scores
of TTH patients were not signiﬁcantly correlated with
the clinical characteristics, apart from moderate correl-
ations of headache severity and the physical and social
dimensions. This may be explained in part by the fact
that this group consisted of a fewer number of patients,
and was itself heterogeneous as regards the headache
frequency of the individuals. On the other hand, areas
conceptually related to QOL, such as the ability to
study, had been found to be more severely aﬀected by
migraine than by TTH, even after correction for pain
intensity (49). Moreover, in the present study signiﬁ-
cant correlations between the TTH group’s clinical
characteristics and SF-36 domains were also very
rare: previous studies about QOL in TTH had similar
results. In a sample of 25 chronic TTH patients, only
four (bodily pain, vitality, social functioning and
mental health) of the eight SF-36 domains were signiﬁ-
cantly correlated with headache frequency, and only
one (social functioning) with headache intensity (50).
In a German study, the SF-36 physical composite
score (PCS) of TTH suﬀerers was signiﬁcantly corre-
lated with days with disability and days with analgesic
use, but not with headache days/hours, days with severe
headache and headache score. In the same study the
PCS of migraineurs was signiﬁcantly correlated with
all clinical variables. Interestingly, the mental health
composite score was not correlated with the clinical
characteristics in either of the diagnostic groups (51).
These studies and our results seem to indicate that the
perceived eﬀect of TTH on QOL is largely independent
of the clinical characteristics of headache.
Convergent validity was assessed by calculating the
correlations between CHQQ and the SF-36 generic
QOL instrument. The total score of our instrument
correlated signiﬁcantly with all SF-36 dimensions in
the whole sample and the diagnostic subgroups, with
the exception of the total score in TTH that was not
correlated with SF-36’s social functioning domain.
CHQQ’s three dimensions had signiﬁcant correlations
with the majority of SF-36’s domains. Most correl-
ations were of moderate strength (0.3 to 0.5) in the
whole sample and migraine group, while there was a
high number of strong (>0.5) correlations between
CHQQ scores and SF-36 domains in the TTH group.
Correlation coeﬃcients were higher in the TTH group
(0.374–0.778) than in the migraine group (0.179–0.487).
The strength of correlations was again similar to those
found in previous validation studies. In the MSQOL
validation study convergent validity was measured by
calculating the correlations of MSQOL with the SF-36
domains: mostly moderate correlations were found
with the exception of a strong (0.53) correlation with
the mental health domain (9). The validation study of
the MSQ2.1 reported low-to-modest correlations
between MSQ dimensions and the two component
scores of the SF-36 (52).
The fact that most correlations were moderate may
be explained by three factors. First, SF-36 gathers data
about the 4 preceding weeks, while the CHQQ asks
questions about the last 2 weeks. Second, there are
important diﬀerences between the items in the two
instruments. The CHQQ asks questions about sleep,
intrafamiliar relations, sex life and leisure activities,
while these are not included in the SF-36.
Furthermore, it is important to stress that the CHQQ
explicitly asks about the way headaches inﬂuence the
various areas, so limitations caused by other conditions
were probably not taken into account by the patients,
whereas SF-36, as a generic QOL measure, gathers
information about the eﬀect of one’s health in general
(including the headaches) on QOL. The same three fac-
tors may also explain the lack of signiﬁcant correlation
between SF-36’s social functioning domain and
CHQQ’s total score in TTH patients.
Confronting the diagnostic subgroups’ headache-
speciﬁc QOL (discriminative or known group validity)
lent further support to the validity of the instrument. It
is important to stress that, as we had expected, migraine
patients had numerically lower scores (worse QOL) for
all items, dimensions and the total score, and that the
diﬀerence was signiﬁcant in most (with the exception of
seven items). It therefore seems that the CHQQ is able
to disclose the diﬀerential eﬀect of headache types on
QOL. In this regard it is worth noting that in the pre-
sent study the SF-36 questionnaire found a signiﬁcantly
diﬀerent QOL between migraine and TTH only in four
of its eight dimensions, and in two of them TTH suf-
ferers had worse QOL, which is not consistent with the
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widespread notion of migraine being a more severe
condition.
Convergent and discriminative validity are two sub-
categories of construct validity. Construct validity
refers to an agreement between a theoretical concept
(‘construct’) and the instrument designed for measuring
it. The necessity of examining the construct validity of
the instruments stems from the fact that an instrument
can only examine the observable aspects of the con-
struct. As the new instrument demonstrated adequate
convergent and discriminative validity, we can assume
that it is in agreement with the construct, i.e. QOL.
We started developing the CHQQ with the intention
of producing an instrument that examines the QOL of
headache patients in detail. We therefore tried to
include a set of items covering several aspects of life.
It was expected that the underlying factor structure
would be complex. In the preliminary study we grouped
the items according to the classical dimension structure
used in QOL research (physical, mental and social),
relying on the content of the items. This is considered
a valid approach. Clinically useful scales are sometimes
organized into subscales according to rational (rather
than mathematical) principles and the two do not
necessarily coincide. An example is the Headache
Disability Inventory (HDI) (53), where the authors
rationally organized items into emotional and func-
tional subscales; in a later study by Holroyd et al. the
factor analysis of HDI items revealed that all items
loaded on a single factor (54). Diﬀerent studies may
ﬁnd a diﬀerent underlying structure within the same
instrument, as exempliﬁed by the MSQOL, which was
found to have three dimensions (avoidance, relation-
ships and feelings) in an American study (16), and
four dimensions (aﬀective, social, energetic and life
rhythms) in a Hungarian one (17).
In the present study the analysis of the item–dimen-
sion correlations conﬁrmed the hypothesized structure
of the instrument.
An obvious issue with our study is the method of
patient selection. As patients presenting at a tertiary
centrewere involved in this study, patients suﬀering from
more severe headaches may have been over-represented
in the sample. In fact, patients with more severe limita-
tions may be more motivated to seek medical help in a
specialized headache centre. An indirect proof of this
possibility may be the fact that migraineurs outnum-
bered TTH suﬀerers in this study, in spite of TTH
being much more prevalent in the general population.
A further limitation of our study is that most of the
patients had migraine. This was due to the fact that we
had chosen to enrol all consecutive outpatients who
fulﬁlled the diagnostic criteria of migraine or TTH.
Although the TTH group was much smaller, the reli-
ability and validity measurements in this subgroup also
showed that the psychometric properties of the instru-
ment were adequate. This was further underscored by
the fact that the instrument showed signiﬁcant diﬀer-
ences between the migraine and TTH groups, with
TTH patients having better QOL. In this respect it is
also worth noting that there were signiﬁcant diﬀerences
in the clinical characteristics of headache in the two
groups, with migraineurs reporting higher values of dis-
ease duration, length of attacks (average, minimum and
maximum), and severity of the attacks. Intriguingly,
those clinical characteristics that were higher in the
TTH group (signifying bigger disease load), i.e. attack
frequency and number of days with headache, were the
ones that showed fewer correlations with CHQQ’s
items, dimensions and total score. A more precise
assessment of the instrument’s usability requires sam-
ples drawn from the general population.
Comparing the new instrument with previously
developed headache-speciﬁc measures could have
added further evidence about the validity of the instru-
ment and may have yielded important data about its
usability. However, due to a lack of validated
Hungarian translations of headache-speciﬁc QOL
instruments, this approach was not possible (the valid-
ation study of the Hungarian version of the MSQOL
was only published in 2011 (17)). Although the HIT-6
has been validated in Hungarian (55), due to the small
sample size (only 35 Hungarian migraineurs diagnosed
by their primary care physician were studied) and to the
fact that, in a strict sense, HIT-6 is not a QOL instru-
ment, we decided not to use it.
Regardless of these limitations, the present study
provides suﬃcient evidence that the new QOL scale is
a reliable and valid instrument to measure QOL in epi-
sodic migraine and TTH. Although previous headache-
speciﬁc instruments are used in headaches other than
migraine, only HIT6 and MQoLQ have been formally
validated in chronic migraine, and, apart from our new
questionnaire, we do not know of any instrument
having been validated for TTH. The present study
paves the way for using the new instrument in these
headache types. We hypothesize that it may be useful
in measuring QOL in headaches other than migraine,
and may oﬀer a more detailed view of the patient’s
QOL, thereby making our understanding of the
burden of headache more complete. It might also be
useful in the more detailed evaluation of headache
treatment (acute or prophylactic), and, assessing its
correlations with instruments measuring patient satis-
faction, might oﬀer insights about the aspects of head-
ache-related QOL that are meaningful for patients.
Further evaluation of the instrument in migraine and
TTH, as well as validation studies in chronic migraine,
cluster headache and medication overuse headache, are
needed to conﬁrm these hypotheses.
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